Potential antidiabetic activity of benzimidazole derivative albendazole and lansoprazole drugs in different doses in experimental type 2 diabetic rats

• Published in: Turkish journal of medical sciences Vol. 51; no. 3; pp. 1579 - 1585
• Main Authors: Dik, Burak, Coşkun, Devran, Bahçivan, Emre, Üney, Kamil
• Format: Journal Article
• Language: English
• Published: Turkey The Scientific and Technological Research Council of Turkey 28.06.2021
• Subjects: Albendazole; Animals; Blood Glucose; Diabetes Mellitus, Experimental - drug therapy; Diabetes Mellitus, Type 2 - drug therapy; Glucose; Glycated Hemoglobin; Hypoglycemic Agents - pharmacology; Insulin; Insulin Resistance; Lansoprazole; Male; Pharmaceutical Preparations; Rats; Rats, Wistar; Triglycerides; antiabetic; HOMA-β; rat; diabetes; Benzimidazole
• ISSN: 1300-0144; 1303-6165
• DOI: 10.3906/sag-2004-38

The aim of this study is to determine the effects of different concentrations of albendazole and lansoprazole, which were benzimidazole derivatives, on endocrinologic and biochemical parameters in experimental type 2 diabetic (T2D) rats. In this study, 46 male Wistar Albino rats were used. Animals were divided as healthy control (0.1 mL/rat/day saline, s.c, n = 6), diabetes control (0.1 mL/rat/day saline, s.c, n = 8), diabetes+low-dose albendazole (5 mg/kg, oral, n = 8), diabetes+high- dose albendazole (10 mg/kg, oral n = 8), diabetes+low-dose lansoprazole (15 mg/kg, subcutaneous, n = 8), and diabetes+high-dose lansoprazole (30 mg/kg, subcutaneous, n = 8). All groups were treated for 8 weeks. The blood samples were analyzed by autoanalyzer and ELISA kits for biochemical and endocrinological parameters, respectively. Glucose, HbA1c, triglyceride, low density cholesterol (LDL), leptin, and Homeostatic Model Assessment for insulin resistance (HOMA-IR) levels increased and insulin and HOMA-β levels decreased in the diabetic rats compared to the healthy control group. The glucose, HbA1c, and triglyceride levels were partially decreased; however, insulin and HOMA-β levels were increased by low-dose albendazole therapy. The high dose of lansoprazole treatment increased insulin level. The lansoprazole and albendazole treatments can be a potential drug or combined with antidiabetic drugs in T2D treatment by Adenosine 5′-monophosphate activated protein kinase (AMPK), peroxisome proliferator-activated receptor (PPAR), incretin-like effect and other antidiabetic mechanisms. It may be beneficial to create an effective treatment strategy by developing more specific substances with benzimidazole scaffold.